Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma

References

• Ramsenthaler C, Osborne TR, Gao W, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer. 2016;16(1):427.
   PubMed Web of Science ®Google Scholar
• Gulbrandsen N, Hjermstad M, Wisloff F, for the Nordic Myeloma Study GroupInterpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol. 2004;72(3):172–180.
   PubMed Web of Science ®Google Scholar
• Manitta V, Zordan R, Cole-Sinclai M, et al. The symptom burden of patients with hematological malignancy: A cross-sectional observational study. J Pain Symptom Manage . 2011;42(3):432–442.
   PubMed Web of Science ®Google Scholar
• Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97(5):416–429.
   PubMed Web of Science ®Google Scholar
• NCI (National Cancer Institute). Surveillance, Epidemiology, and End Results (SEER). Program. SEER Stat Fact Sheets: Myeloma. [cited 2020 Apr 18]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html.
   Google Scholar
• Kristinsson SY, Anderson WF, Landgren O. Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia. 2014;28(6):1346–1348.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–1769.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Weisel K, Ludwig H, Rieth A, et al. Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data. Qual Life Res. 2020;29(1):69–79.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Dimopoulos MA, Masszi T, et al. Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Cin Oncol. 2016;34(32):3921–3930.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA Center for Devices and Radiological HealthGuidance for industry. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009. Available from: https://www.fda.gov/ downloads/drugs/guidances/ucm193282.pdf.
   Google Scholar
• Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249–4255.
   PubMed Web of Science ®Google Scholar
• Weisel K, Dimopoulos M, Moreau P, et al. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. Leuk Lymphoma. 2020;9:1–10.
   Google Scholar
• Martino M, Rossi M, Ferreri A, et al. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. Expert Rev Hematol. 2019;12(8):665–684.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, International Myeloma Workshop Consensus Panel 1, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Stead ML, Brown JM, Velikova G, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol. 1999;104(3):605–611.
   PubMed Web of Science ®Google Scholar
• Cocks K, Cohen D, Wisloff F, EORTC Quality of Life Group, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670–1678.
   PubMed Web of Science ®Google Scholar
• Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–415.
   PubMedGoogle Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–592.
   PubMed Web of Science ®Google Scholar
• Sully K, Trigg A, Bonner N, et al. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. Eur J Haematol. 2019;103(5):500–509.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing 2020. R Foundation for Statistical Computing, Vienna, Austria. Available from: https://www.R-project.org/.
   Google Scholar
• Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781–794.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services FDA. Guidance for Industry, patient-reported outcome measures: use in medical product development to support labeling claims. Maryland: US Department of Health and Human Services FDA; 2009.
   Google Scholar
• Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Am J Hematol. 2018;93(8):985–993.
   Web of Science ®Google Scholar
• Weisel K, Dimopoulos M, Song KW, et al. Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial. Clin Lymphoma Myeloma Leuk. 2015;15(9):519–530.
   PubMed Web of Science ®Google Scholar
• Quality of life and clinical trials. Lancet. 1995;346:1–2.
   PubMed Web of Science ®Google Scholar
• Kvam AK, Fayers P, Hjermstad M, et al. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol. 2009;83(4):279–289.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Sprangers MA. Quality-of-life assessment in oncology. Achievements and challenges. Acta Oncol. 2002;41(3):229–237.
   PubMed Web of Science ®Google Scholar
• Calvert M, Blazeby J, Altman DG, CONSORT PRO Group, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–822.
   PubMed Web of Science ®Google Scholar
• Hari P, Romanus D, Luptakova K, et al. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. J Geriatric Oncol. 2018;9(2):138–144.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Verelst SG, Lewis P, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27(10):1959–1969.
   PubMed Web of Science ®Google Scholar
• Leleu X, Kyriakou C, Vande Broek I, et al. Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. Blood Cancer J. 2017;7(3):e543–e543.
   PubMedGoogle Scholar